J&J, Bayer’s Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization
Johnson & Johnson and Bayer’s Xarelto, once king of the warfarin alternative market, is now chasing chasing Pfizer and Bristol-Myers Squibb’s Eliquis. But with a new approved indication in the books—its eighth—it’s not backing down. The FDA on Monday approved Xarelto to help prevent blood clots for acutely ill patients without a high risk of bleeding during… Read More »